The Management Board of Scope Fluidics S.A. (the “Company”) would like to announce that the second stage of R&D works on the PCR|ONE system has been completed, in line with the schedule provided in the Company’s Information Statement of 24 July 2017.
Completed stage: “Achieving readiness for system industrialization”.
As a part of a report on delivery related to the current milestone task (the “Report”), the course of current negotiations with potential partners on chip and analyzer industrialization and delivery of reagents has been summarized. As a result of these negotiations, the Company obtained information on the market possibilities and conditions for the PCR|ONE system industrialization process, as well as its individual stages. Moreover, further actions aimed at the industrialization of the system during the first three quarters of 2018 have been planned.
Furthermore, as a part of the Report:
- a design of a production line for a series of 1-2 thousand ready-to-use diagnostic chips has been prepared;
- analysis of the PCR|ONE system certification process in Europe has been conducted; and the first four countries in which the system is to be registered have been selected;
- recommendations for further research works which define the research tasks to be conducted during the first three quarters of 2018 have been drafted.